1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Pfizer Aims To Have First PD-1 Inhibitor Approved In Early NMIBC Setting

 
• By Alaric DeArment

The drug maker announced positive topline Phase III results for its subcutaneous PD-1 inhibitor sasanlimab in first-line, BCG-naïve non-muscle invasive bladder cancer combined with BCG.

Bladder cancer medical concept as an anatomical organ symbol with microscopic malignant cells spreading in the human body as a health care 3D illustration.

Pfizer is pushing ahead with its effort to jump back into immune checkpoint inhibitor therapy with new Phase III results showing efficacy for its subcutaneous PD-1 inhibitor sasanlimab in non-muscle invasive bladder cancer (NMIBC).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

BeiGene Ends Anti-TIGIT Development In Lung Cancer

 
• By Joseph Haas

BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.

Merck Gets Closer To Extending Keytruda Franchise With Subcutaneous Version

 
• By Alaric DeArment

Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.

Rybrevant/Lazcluze Survival Win Could Overcome Tagrisso’s Convenience Advantage

 
• By Alaric DeArment

J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.

BioNTech Seeks New Partners To Boost PD-L1xVEGF Competitor

 
• By Andrew McConaghie

Increasingly focused on maximizing and accelerating the progress of its PD-L1 x VEGF inhibitor BNT357, the company expects new partnerships to be announced this year.

More from Scrip

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Pipeline Growth Slowed In 2024 But Oncology And Neurologicals Held Strong

 
• By Alexandra Shimmings

There was a reduction in the rate of expansion of the pharma pipeline last year but 2024 also saw another welcome increase in the number of drug candidates in Phase III following years of stagnation.

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.